These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 31317789)

  • 1. Functionalized ligands targeting G protein-coupled adenosine receptors.
    Federico S; Spalluto G
    Future Med Chem; 2019 Jul; 11(14):1673-1677. PubMed ID: 31317789
    [No Abstract]   [Full Text] [Related]  

  • 2. The identification of high-affinity G protein-coupled receptor ligands from large combinatorial libraries using multicolor quantum dot-labeled cell-based screening.
    Fu J; Lee T; Qi X
    Future Med Chem; 2014 May; 6(7):809-23. PubMed ID: 24941874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging Approaches to GPCR Ligand Screening for Drug Discovery.
    Kumari P; Ghosh E; Shukla AK
    Trends Mol Med; 2015 Nov; 21(11):687-701. PubMed ID: 26481827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric inhibition of g-protein coupled receptor oligomerization: strategies and challenges for drug development.
    Hurevich M; Talhami A; Shalev DE; Gilon C
    Curr Top Med Chem; 2014; 14(15):1842-63. PubMed ID: 25175995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GPCR profiling: from hits to leads and from genotype to phenotype.
    Cvijic ME; Sum CS; Alt A; Zhang L
    Drug Discov Today Technol; 2015 Nov; 18():30-7. PubMed ID: 26723890
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward multivalent signaling across G protein-coupled receptors from poly(amidoamine) dendrimers.
    Kim Y; Hechler B; Klutz AM; Gachet C; Jacobson KA
    Bioconjug Chem; 2008 Feb; 19(2):406-11. PubMed ID: 18176997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studying GPCR conformational dynamics by single molecule fluorescence.
    Quast RB; Margeat E
    Mol Cell Endocrinol; 2019 Aug; 493():110469. PubMed ID: 31163201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug-Target Interactions.
    Lu S; Zhang J
    J Med Chem; 2019 Jan; 62(1):24-45. PubMed ID: 29457894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Retinoid and Non-Retinoid Ligands of the Rod Visual G Protein-Coupled Receptor.
    Ortega JT; Jastrzebska B
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Pharmacochaperone-Based High-Throughput Screening Assay for the Discovery of Chemical Probes of Orphan Receptors.
    Morfa CJ; Bassoni D; Szabo A; McAnally D; Sharir H; Hood BL; Vasile S; Wehrman T; Lamerdin J; Smith LH
    Assay Drug Dev Technol; 2018 Oct; 16(7):384-396. PubMed ID: 30251873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time-resolved FRET strategy to screen GPCR ligand library.
    Oueslati N; Hounsou C; Belhocine A; Rodriguez T; Dupuis E; Zwier JM; Trinquet E; Pin JP; Durroux T
    Methods Mol Biol; 2015; 1272():23-36. PubMed ID: 25563174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily.
    Roth BL; Kroeze WK
    J Biol Chem; 2015 Aug; 290(32):19471-7. PubMed ID: 26100629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GPCR structures in drug design, emerging opportunities with new structures.
    Tautermann CS
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4073-9. PubMed ID: 25086683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands.
    Festa C; Renga B; D'Amore C; Sepe V; Finamore C; De Marino S; Carino A; Cipriani S; Monti MC; Zampella A; Fiorucci S
    J Med Chem; 2014 Oct; 57(20):8477-95. PubMed ID: 25247751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoting neurotrophic effects by GPCR ligands.
    Jeanneteau F; Chao MV
    Novartis Found Symp; 2006; 276():181-9; discussion 189-92, 233-7, 275-81. PubMed ID: 16805430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assay strategies for identification of therapeutic leads that target protein trafficking.
    Conn PM; Spicer TP; Scampavia L; Janovick JA
    Trends Pharmacol Sci; 2015 Aug; 36(8):498-505. PubMed ID: 26067100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in the rationale design of GPER ligands.
    Rosano C; Lappano R; Santolla MF; Ponassi M; Donadini A; Maggiolini M
    Curr Med Chem; 2012; 19(36):6199-206. PubMed ID: 23116143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photoswitching the Efficacy of a Small-Molecule Ligand for a Peptidergic GPCR: from Antagonism to Agonism.
    Gómez-Santacana X; de Munnik SM; Vijayachandran P; Da Costa Pereira D; Bebelman JPM; de Esch IJP; Vischer HF; Wijtmans M; Leurs R
    Angew Chem Int Ed Engl; 2018 Sep; 57(36):11608-11612. PubMed ID: 29926530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CRE luc bioluminescence transgenic mouse model for detecting ligand activation of GPCRs.
    Dressler H; Economides K; Favara S; Wu NN; Pang Z; Polites HG
    J Biomol Screen; 2014 Feb; 19(2):232-41. PubMed ID: 23896687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lighting up G protein-coupled purinergic receptors with engineered fluorescent ligands.
    Ciruela F; Fernández-Dueñas V; Jacobson KA
    Neuropharmacology; 2015 Nov; 98():58-67. PubMed ID: 25890205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.